Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
The company will license EGFR and cMet inhibitors from Celyn.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
After several discontinuations, a new ADC enters the clinic.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
